Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285886 | 1.00 | KCNH2 (0.31) | KCNH2 | |
| SCHEMBL1712374 | 0.78 | KCNH2 (0.32) | KCNH2 | |
| SCHEMBL1724100 | 0.78 | GSK3B (0.33) | KCNH2 | |
| SCHEMBL1712671 | 0.78 | KCNH2 (0.32) | KCNH2 | |
| SCHEMBL2287760 | 0.78 | HTR1A (0.40) | — | |
| SCHEMBL1723323 | 0.74 | PRKCA (0.34) | KCNH2 | |
| SCHEMBL3786929 | 0.72 | — | — | |
| SCHEMBL1712013 | 0.71 | ACACB (0.39) | — | |
| SCHEMBL3349228 | 0.71 | — | — | |
| SCHEMBL1723660 | 0.71 | NPC1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-11 | — | — | US | disclosed |
| EP-2344495-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | HRH3, OXA1L, HRH1 | KCNH2 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.